60 results about "Pharmacology" patented technology

A method for treating a subject afflicted with an autoimmune disease with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of administering a therapeutic amount of the pharmaceutical composition to the subject, determining whether the subject is a glatiramer acetate responder or a glatiramer acetate hypo- / non-responder by measuring the value of a biomarker selected from the group consisting of IL-10 concentration, IL-17 concentration, IL-18 concentration, TNF-α concentration, BDNF concentration, caspase-1 concentration, IL-10 / IL-18 ratio and IL-10 / IL-17 ratio in the blood of the subject, and comparing the measured value to a reference value for the biomarker to identify the subject as a glatiramer acetate responder or a glatiramer acetate hypo- / non-responder, and continuing the administration if the subject is identified as a glatiramer acetate responder, or modifying treatment of the subject if the subject is identified as a glatiramer acetate hypo- / non-responder.

The hemitartrate salt of a compound represented by the following structural formula: (Formula I Hemitartrate), which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of the Formula (I) Hemitartrate are characterized by a variety of properties and physical measurements. As well, methods of producing crystalline Formula (I) Hemitartrate, and using it to inhibit glucosylceramide synthase or lowering glycosphingolipid concentrations in subjects to treat a number of diseases, are also discussed. Pharmaceutical compositions are also described.

The invention provides a wound cleaning liquid, which comprises an active component, an osmotic pressure regulator and deionized water; the active component is one or more from a wormwood extract, an aloe extract and a mint extract. The wound cleaning liquid provided by the invention has no stimulation to a wound, can clean the wound, also has bactericidal, anti-inflammatory, analgesic, and wound healing promoting effects, and scars are not easy to leave.

The invention relates to a preparation method of a telmisartan intermediate, namely 2-n-propyl-4-methyl-6-Benzimidazolecarboxylic acid. The preparation method of the 2-n-propyl-4-methyl-6-Benzimidazolecarboxylic acid comprises the following steps: firstly, ethanol hydrochloride acts with butyronitrile and anhydrous hydrogen chloride within the range of 0-35 DEG C; the mixture obtained in the firststep reacts with 3-methyl-4-aminobenzoic acid and ice vinegar within the range of pH 5.0-11.0 at the controlled temperature of 10-40 DEG C, and an intermediate shown in the formula II is obtained; and then the intermediate shown in the formula II reacts with a sodium hypochlorite solution, and the 2-n-propyl-4-methyl-6-Benzimidazolecarboxylic acid is obtained. The intermediate preparation processis suitable for industrial production, and meanwhile the product quality is improved.

This antiseptic agent composition, which is characterized by containing as effective ingredients 2-methyl-4,5-trimethylene-4-isothiazolin-3-one, and 2-methyl-4-isothiazolin-3-one and / or a compound represented by general formula (1), provides an antiseptic agent having exceptional antiseptic effect and being useable at low concentration.

The invention provides a use of an effective part of a traditional Chinese medicine in HIV latency-resistant treatment. Through an ingenious activity screening method, it is found that a traditional Chinese medicine rhizoma atractylodis macrocephalae has effects of resisting AIDS. Through a solvent extraction method, a gradient extraction method, a silica gel column chromatography and the combination with activity screening, an effective part of rhizoma atractylodis macrocephalae is determined and is prepared. The prepared effective part of rhizoma atractylodis macrocephalae can be used as an active component for resisting AIDS. The effective part of rhizoma atractylodis macrocephalae has an effect of HIV latency intervention, can be combined with a drug for resisting retroviruses, can accelerate the removal of latent virus reservoirs, and provides a novel approach for thorough curing of AIDS.

The invention relates to a method for preparing a medicament for treating leucopenia. The preparation method comprises the following steps of: taking medicinal materials in a ratio, adding 60 to 80 percent ethanol in an amount which is 6 to 10 times the weight of the medicinal materials, performing reflux extraction for 2 to 4 times and 1 to 3 hours every time, combining the ethanol extracts, and recovering the ethanol till the ethanol smell does not exist to obtain paste; decocting the medicinal residue for 2 to 4 hours and 1 to 3 hours every time by adding water in an amount which is 4 to 6 times the weight of the medicinal residue, combining the decoction, and concentrating; and combining the medicinal paste, concentrating the medicinal paste into thick paste under reduced pressure, adding available medicinal accessories into the thick paste, thus obtaining a clinical available preparation. The medicament has the effects of nourishing liver and kidney and tonifying qi and blood, and is clinically used for treating the leucopenia produced after malignant tumor radiotherapy and chemotherapy.

The invention relates to an aerosol precursor with external medicine components for treating rhinitis. The aerosol precursor comprises glycerin, propylene glycol, 1,3-butanediol, a flavor component and an external medicine extract for treating rhinitis, wherein the mass ratio of glycerin to propylene glycol, 1,3-butanediol to a flavor component and the external medicine extract is (40-45):(20-25):(0-10):(0-10):(1-10). The invention further relates to a method for dispersing the external medicine components in the external medicines for treating rhinitis into nano-order fogdrops, and further relates to aerosol containing the nano-order fogdrops. The aerosol precursor provided by the invention comprises the external medicine effect components for treating rhinitis, nano-order fogdrops can be obtained when the external medicine effect components are heated in an electronic smoke instrument with an electric heating device, and the medicine effect components can be relatively well absorbed by human bodies.

The invention discloses a kit for detecting valproic acid drug concentration in dry blood spots. The kit comprises a kit body, a first container, a calibrator card and a quality control card, whereinthe calibrator card is a blood spot collection card fixed with a group of valproic acid dry blood spot samples as dry blood spot calibration points, and the number of the dry blood spot calibration points is at least six, the quality control material card is a blood spot collection card fixed with at least one group of valproic acid dry blood spot samples as dry blood spot quality control points,the number of each group of dry blood spot quality control points is at least three, the first container is filled with an internal standard extracting solution, and an internal standard adopts isotopic substituted valproic acid. The invention further discloses a detection method of the kit. The kit provided by the invention has advantages of simple preparation of reagents, less required amount ofsamples, convenience in storage and transportation, rapid pretreatment, short analysis period, lower cost and the like, and is suitable for popularization in clinical conventional detection.

The invention discloses a traditional Chinese medicine preparation for treating the hyperplasia of mammary glands. The traditional Chinese medicine preparation accords with the theory of Chinese herb compatibility, aiming at the fundamental effect, the Indian kalimeris herb, abrus cantoniensis hance, spina gleditsiae, fructus liquidambaris, herba lycopi, musk, alangium leaf, trichosanthes kirilowii Maxim and farfugium japonicum are taken as the monarch drugs for promoting circulation and removing stasis, and dredging breast collaterals; the hemistepta lyrata, the seed of cowherb, felwort, adiantum caudatum, silkworm larva, dandelion and radix rhapontied are taken as the ministerial drugs for reducing swelling and resolving mass, and softening hard mass and stopping pain; the radix curcumae, radix polygonati officinalis, frankincense, rhizoma cyperi, tribulusterrestris, suncured ginseng, cistanche and salvia miltiorrhiza are taken as the adjuvant drugs with coordinating effect, for soothing the liver and regulating vital energy, nourishing the five organs, benefiting the vital essence and reinforcing the functions of the monarch drugs and the ministerial drugs and restraining the toxic side effect of the other medicines. Many medicines are simultaneously used with mild medical effect and permanent effectiveness, so that the functions of promoting qi circulation and stopping pain, removing toxicity and dispersing swelling, calming the liver and dispelling melancholy, and softening hardness to dissipate stagnation can be reached, and the hyperplasia of mammary glands can be cured.

The present invention relates to a MDR reversal agent. The agent is polyvalent possessing two or more binding domains spaced to effectively inhibit the multiple drug resistance activity of Pgp. The MDR reversal agent is based upon the naturally occurring compound (-)-stipiamide. The multiple drug resistence reversal agent of the present invention can be a homodimer based on napthyl-DHS. The homodimer incorporates two napthyl-DHS domains joined by a series of joined ethylene glycol spacers. The invention also relates to method of reversing MDR in a human cell by administering the reversal agent of the invention. When Pgp is contacted with the reversal agent, the ATPase activity of Pgp is significantly reduced as well as the binding affinity of Pgp for its known substrates.

The invention discloses a novel benzimidazole isomer preparation. The novel benzimidazole isomer preparation is prepared from the following components in parts by weight: 1-1.5 parts of omeprazole, 1-1.5 parts of berberine hydrochloride, 50-60 parts of sodium bicarbonate, 45-50 parts of magnesium hydrate, 2-3 parts of oligoester beta-cyclodextrin, 20-30 parts of oleic acid and 80-95 parts of injection water. The invention also discloses a preparation method of the novel benzimidazole isomer preparation. Omeprazole and berberine hydrochloride disclosed by the invention have synergistic effects; and the berberine hydrochloride not only can prompt the omeprazole to restrain gastric acid secretion and increase effect, but also effectively reduces the adverse effects rate. The oligoester beta-cyclodextrin is also introduced into the novel benzimidazole isomer preparation, so that the effective ingredients omeprazole and berberine hydrochloride are coated by the oligoester beta-cyclodextrin; the water solubility is effectively improved; the oligoester beta-cyclodextrin is mixed into oleinic acid, so that emulsification of the oligoester beta-cyclodextrin is also further prompted; the conditions of uneven distribution such as suspension or sedimentation are prevented; and the curative effect is greatly improved.

Treating subjects having a lipid storage disorder with a composition comprising a PKC activator, such as bryostatins, bryologs, and polyunsaturated fatty acids. Accordingly, the present disclosure provides methods for treating human subjects suffering from lipid storage disorders, such as Niemann-Pick disease, by administering PKC activators. The present disclosure provides, according to certain embodiments, methods comprising administering to a subject with Niemann-Pick Type C disease a pharmaceutically effective amount of bryostatin 1.

The invention discloses a traditional Chinese medicine preparation for osteoporosis, osteonecrosis, bone generation and blood circulation promotion. The traditional Chinese medicine preparation is prepared from premna fulva Craib, sarcandra twigs and leaves, natural copper, red sage roots, corydalis tubers, twotoothed achyranthes roots and eucommia bark. The invention also provides a preparation method of the traditional Chinese medicine preparation. According to the principle of combining the traditional Chinese medicine theory and the western medicine theory, the traditional Chinese medicinepreparation provided by the invention is scientifically proportioned, and the traditional Chinese medicines are matched with each other to offset weakness, so that traditional Chinese medicine preparation has the effects of promoting blood circulation and removing blood stasis, dredging collaterals and setting bones, relieving swelling and pain, and strengthening tendons and bones, and has obvious effects on treating fracture, osteoporosis and osteonecrosis. Pharmacodynamic and toxicological tests show that the traditional Chinese medicine preparation has obvious effects, has no toxic or sideeffects, and overcomes the defects that western medicines can damage liver and kidney functions and the like after being taken for a long time. The traditional Chinese medicine preparation prepared by using a folk secret prescription of the Zhuang nationality can be prepared into various dosage forms, is convenient and safe to carry and take, and reduces or avoids danger, injury and pain caused by intravenous drip and intramuscular injection treatment. The traditional Chinese medicine preparation has advantages of short treatment course, quick response and wide application range, and has a wide application prospect.

The invention discloses a preparation method of a compound I, especially an isomer Ia thereof. The preparation method provided by the invention does not need extraction, washing, drying, concentration and other operations, post-treatment is simple, industrial production is facilitated, the preparation method is high in yield, the obtained product only contains one impurity, and subsequent quality control is facilitated.